Minerva Neurosciences, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Unaudited results cover the three months ended March 31, 2024. Minerva is a clinical-stage biopharmaceutical company developing roluperidone for schizophrenia and holds rights to MIN-301 for Parkinson’s disease. It has no commercially approved products and reported no product revenue.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None from product sales; no clear revenue value is presented in the statements of operations |
| Research and development expense | $4.17 million | $2.65 million; up about $1.51 million |
| General and administrative expense | $2.51 million | $2.69 million; down about $0.18 million |
| Total operating expenses / operating loss | $6.68 million | $5.35 million |
| Net loss | $8.57 million | $6.97 million |
| Net loss per share, basic and diluted | $1.13 | $1.31 |
| Net cash used in operating activities | $6.09 million | $0.12 million |
No meaningful operating margin is reported because the company has no product revenue. Cash, cash equivalents and restricted cash totaled $34.92 million at quarter-end, down $6.09 million during the quarter; unrestricted cash and equivalents were $34.82 million. Current assets were $35.62 million and current liabilities $2.83 million. Total liabilities were $87.10 million, including an $84.27 million liability related to the sale of future royalties; stockholders’ deficit was $36.59 million. The royalty liability is recorded under debt accounting and is not presented as conventional term debt.
Material developments, outlook and risks
- On February 26, 2024, the FDA issued a Complete Response Letter for roluperidone. The FDA said the existing efficacy evidence was insufficient on its own and cited missing evidence on use with antipsychotics, clinical meaningfulness of symptom changes, and long-term safety at the proposed dose. The FDA called for at least one additional positive, adequate, well-controlled study and additional supporting data.
- Minerva completed the Phase 1b MIN-101C18 study of roluperidone with olanzapine during Q1. Preliminary results from 17 enrolled patients indicated no new safety signals and no relevant pharmacokinetic interaction; 13 completed all 17 days of dosing. These findings do not resolve the FDA’s request for additional efficacy and safety evidence.
- R&D expense increased, primarily reflecting FDA review costs and the MIN-101C18 study. Net loss widened, while loss per share improved because weighted-average shares were higher.
- Management expects continuing losses and negative operating cash flows, but believes cash and restricted cash at March 31 will cover operating commitments for at least 12 months after issuance of the financial statements. It also says additional capital will be needed for continued operations and later-stage development; financing may be unavailable or dilutive, and operations could be scaled back or discontinued if funding cannot be secured.
- After quarter-end, Nasdaq notified Minerva on April 10 that its market value of listed securities had been below the $35 million minimum for 31 consecutive business days. The company has until October 7, 2024 to regain compliance or may face delisting, which could impair liquidity and access to capital.
- Cash used in operations rose sharply from Q1 2023; the prior-year period benefited from a $3.12 million decrease in refundable regulatory fees. The company had no investing or financing cash flows in either quarter. It had $22.6 million eligible for sale under its ATM program at March 31, with no ATM shares sold in Q1.
- Other key risks include clinical and regulatory uncertainty, the need for further financing, potential share dilution, and data privacy and cybersecurity exposure. The company reported no legal proceeding expected to have a material adverse effect.
Key facts investors should verify
- What additional roluperidone study and supporting data the FDA will require, and the expected cost, timing and feasibility of completing them.
- Whether the company can regain Nasdaq’s market-value compliance by October 7, 2024 and maintain its listing.
- Whether management’s stated cash runway remains achievable as trial plans and spending evolve, and what financing alternatives are available.
- The assumptions behind the $84.27 million royalty-sale liability and its non-cash interest expense, which uses estimates of future royalty and milestone payments.
- The status and prospects of Janssen’s remaining Phase 3 seltorexant study and any potential milestones payable under the royalty-sale arrangement.